FDA Authorizes Marketing of the First Genetic Test to Aid in the Diagnosis of Fragile X Syndrome

February 21, 2020 FDA

Today, FDA authorized marketing of the first test to detect a genetic condition known as Fragile X Syndrome (FXS), the most common known cause of inherited developmental delay and intellectual disability.

Previous Article
FDA Takes New Steps to Increase the Safety of Laparoscopic Power Morcellators when used in Gynecologic Surgeries
FDA Takes New Steps to Increase the Safety of Laparoscopic Power Morcellators when used in Gynecologic Surgeries

FDA takes several steps to make the use of laparoscopic power morcellators safer in gynecologic surgeries: ...

Next Article
FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process
FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process

FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process